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Glossary of Abbreviations: 24 
CM: conditioned medium 25 
cMC: conditioned media control 26 
dP/dt: the derivative of left ventricular pressure over time 27 
Exo: exosomes 28 
EVs: extracellular vesicles 29 
H&E: hematoxylin and eosin 30 
I/R: ischemia/reperfusion 31 
LVDP: left ventricular developed pressure 32 
miR: micro-RNA 33 
MSC: mesenchymal stem cell 34 
RPP: rate pressure product 35 
TEM: transmission electron microscope 36 
UW: University of Wisconsin 37 
38 
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Central Picture: 41 
Central picture legend: MSC secretions improve donor heart preservation, thus improving graft 42 
function post-surgery. 43 
44 
Central Message: When added to ex-vivo preservation solution, MSC-CM and MSC-EVs 45 
ameliorate cold ischemia-induced myocardial damage in donor hearts and improve donor heart 46 
function post transplantation. 47 
48 
Perspective Statement: Our findings provide a foundation to develop cell-free, stem cell 49 
secretion-based therapies for optimizing current storage methods of donor organs, thus 50 
prolonging the time for ex-vivo preservation of donor hearts, increasing the usage of available 51 
donor organs, and improving graft function and patient outcomes post-transplantation. 52 
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Abstract 53 
Objectives: Heart transplantation is the gold standard of treatments for end-stage heart failure, 54 
but its use is limited by extreme shortage of donor organs. The time “window” between 55 
procurement and transplantation sets the stage for myocardial ischemia/reperfusion injury (I/R), 56 
which constrains the maximal storage time and lowers utilization of donor organs. Given 57 
mesenchymal stem cell (MSC)-derived paracrine protection, we aimed to evaluate the efficacy of 58 
MSC-conditioned medium (MSC-CM) and extracellular vesicles (MSC-EVs) when added to ex-59 
vivo preservation solution on ameliorating I/R-induced myocardial damage in donor hearts.  60 
Methods: Mouse donor hearts were stored at 0-4°C of <1hr-cold ischemia (<1hr-I), 6hr-I + 61 
vehicle, 6hr-I + MSC-CM, 6hr-I + MSC-EVs, and 6hr-I + MSC-CM from MSCs treated with 62 
exosome release inhibitor. The hearts were then heterotopically implanted into recipient mice. At 63 
24-hour post-surgery, myocardial function was evaluated. Heart tissue was collected for analysis 64 
of histology, apoptotic cell death, microRNA (miR)-199a-3p expression, and myocardial 65 
cytokine production. Results: 6hr-cold ischemia significantly impaired myocardial function, 66 
increased cell death, and reduced miR-199a-3p in implanted hearts vs. <1hr-I. MSC-CM or 67 
MSC-EVs in preservation solution reversed detrimental effects of prolong cold ischemia on 68 
donor hearts. Exosome-depleted MSC-CM partially abolished MSC secretome-mediated 69 
cardioprotection in implanted hearts. MiR-199a-3p was highly enriched in MSC-EVs. MSC-CM 70 
and MSC-EVs increased cold ischemia-downregulated miR-199a-3p in donor hearts, whereas 71 
exosome-depletionneutralized this effect. Conclusions: MSC-CM and MSC-EVs confer 72 
improved myocardial preservation in donor hearts during prolonged cold static storage and 73 




Heart transplantation is the effective treatment for end-stage heart failure, but its use is 77 
limited by extreme shortage of donor organs. Due to the insufficient number of suitable donor 78 
hearts, more than a third of patients are either permanently removed from waiting lists or die 79 
before receiving transplants 1. Therefore, it is critical to increasing the number of suitable donor 80 
hearts for transplantation. Currently, cold static storage remains the gold standard for organ 81 
preservation. However, it is associated with cold ischemia, the prolongation of which is an 82 
independent risk factor for primary graft failure and recipient death after transplantation 2, 3, thus 83 
limiting the maximal storage time to 4-6 hours 4.  Generally, the ischemia/reperfusion (I/R) 84 
injury progressively deteriorates graft and patient outcomes beyond this time. Modification of 85 
organ preservation solution to prolong the time for ex-vivo preservation of donor hearts is 86 
appealing. Particularly, this affects potential recipients in distant geographical areas. 87 
Mesenchymal stem cell (MSC)-based therapy represents one of promising approaches for 88 
treatment of ischemic tissues/organs. Accumulating studies from clinical trials have revealed its 89 
safety and practicality, as well as the potential effectiveness in treating ischemic heart disease 5-8. 90 
Compelling evidence from others and our group has demonstrated that MSC paracrine action is 91 
the primary mechanism to mediate tissue protection from ischemia 9-16. We have shown that pre-92 
treatment with human MSCs acutely improve myocardial functional recovery following I/R 93 
injury 10. We have also demonstrated that using MSCs significantly protects myocardium from 94 
the ischemic injury in both in-vivo and ex-vivo study 9. Of note, emerging evidence has suggested 95 
MSC-derived exosomes (MSC-Exo) could emulate MSC secretome-mediated cardiac protection 96 
17. Surprisingly, no study has reported using MSC secretome, particularly exosomes, to reduce97 
ischemic injury in donor hearts during preservation. Accordingly, we are the first to evaluate the 98 
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MSC conditioned medium (CM) and their exosomes as an adjunct to standard preservation 99 
solution on ameliorating cold ischemia-induced damage in donor organs during ex-vivo storage 100 
by using an in-vivo murine cervical heterotopic heart transplantation model. 101 
Methods and Materials 102 
Animals 103 
Adult (12-16 weeks) male C57BL/6J mice were purchased from the Jackson Laboratories 104 
and acclimated for > 5 days before experiments. The animal protocol was reviewed and 105 
approved by the Institutional Animal Care and Use Committee of Indiana University. All 106 
animals received humane care in compliance with the Guide for the Care and Use of Laboratory 107 
Animals (NIH Pub. No. 85-23, revised 1996). 108 
Preparation of human MSC-CM and MSC-derived extracellular vesicles (EVs) 109 
Human MSCs were harvested from healthy male human bone marrow and purchased 110 
from the Lonza Inc. (PT-2501). The cells were cultured with MSC basal medium + MSC growth 111 
bulletkit (Lonza) based on the manufacturer’s instructions and our previous experience 13. The 112 
medium was changed every 3 days.  CM was generated as shown in Figure S1A. After 72hr-113 
cultivation, the medium was collected and centrifuged at 3000g for 15 minutes. The supernatant 114 
was then sequentially concentrated to 100-fold by centrifugation through the Amicon Ultra 115 
Centrifugal Filter (membranes cutoff >3 kDa, EMD Millipore) as we previously described 18. 116 
The concentrated CM from the filtrate tube of the top unit was diluted in University of 117 
Wisconsin (UW) solution to the final concentration as indicated in Figure S1A. The MSC-CM 118 
from the centrifuge tube of the bottom unit that did not contain soluble factors >3 kDa and EVs 119 
was used as conditioned media control (cMC). 120 
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EVs were isolated from the concentrated MSC-CM using ExoQuick-TC exosome 121 
isolation kit (System Biosciences) (Fig. S1A). EV pellets were re-suspended with PBS and 122 
stored at -80°C. The morphology of exosomes was determined by transmission electron 123 
microscope (TEM). Size distribution of EVs was measured by Nanosight analysis. 124 
The MSC-CM was further collected from MSCs treated with 10 µM GW4869 (an 125 
exosome release inhibitor) for 72hr 19 to investigate the therapeutic effect of exosome-depleted 126 
MSC-CM (Fig. S1B). 127 
Murine Cervical Heterotopic Heart Transplantation 128 
After C57BL/6 mice were anesthetized and heparinized, donor hearts were flushed with 129 
1ml of cold UW containing vehicle, MSC-CM, or MSC-EVs via the ascending aorta. After 130 
excision, these hearts were stored in the same solution at 0-4°C. After storage, donor hearts were 131 
heterotopically implanted into male syngeneic C57BL/6 recipients 20. Briefly, recipient mouse 132 
was anesthetized with isoflurane and placed in a supine position on a warm (37°C) pad under an 133 
operating microscope. A skin incision was made from the jugular notch to the right lower 134 
mandible. The right lobe of the submandibular gland was removed to provide the space for 135 
placing donor heart. The right external jugular vein and the common carotid artery were 136 
mobilized and divided.  The cuff was passed through these vessels, respectively. The vessels of 137 
donor heart were connected to the recipient as follows: donor pulmonary artery to recipient right 138 
external jugular vein and donor aorta to recipient common carotid artery. The surgical procedure 139 
for these anastomoses between the graft and the recipient was shown in video 1. After removing 140 
the clamp on the right external jugular vein and the carotid artery, the implanted heart was filled 141 
with blood instantly and started beating within two minutes. After the implanted heart beating 142 
normally, the skin was closed. At 24 hours post-implantation, myocardial function (left 143 
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ventricular developed pressure [LVDP], heart rate, and +/- dP/dT) was detected in transplanted 144 
hearts using a Millar Mikro-Tip pressure catheter (SPR-671, Millar Inc.) that was inserted into 145 
the LV of the implanted heart in recipient animals under isoflurane anesthesia. Data were 146 
recorded using a PowerLab 8 data acquisition digitizer (ADInstruments Inc.). The pulse pressure 147 
difference was measured by inserting Millar pressure catheter into abdominal aorta of recipient 148 
mice. Native and donor heart rates were also recorded by electrocardiogram (ECG). 149 
A total of 54 donor hearts were randomly divided into groups of: 1) <1hr-cold storage as 150 
baseline control (<1hr-I); 2) 6hr-I + basal medium without cell cultivation (6hr-I + vehicle); 3) 151 
6hr-I + MSC-CM (6hr-I + CM); 4) 6hr-I + MSC-EVs; and 5) 6hr-I + MSC-CMGM4869.  Within 24 152 
hours, seven recipients (13%) were dead or experienced with a non-beating implanted heart due 153 
to twisted anastomosis vessels and/or thrombosis. These animals were excluded from further 154 
analysis. At 24 hours post-implantation, the remaining recipient mice were euthanized for 155 
harvesting donor hearts. 156 
Histological Analysis 157 
After grafts were collected, a portion (cross-section) of heart tissue was fixed in 10% 158 
buffered formaldehyde, embedded in paraffin, and then sectioned for hematoxylin and eosin 159 
(H&E) staining.  The graft damage was determined in H&E-stained sections in a blinded-fashion 160 
by scientists of the Pathology & Laboratory Medicine. 161 
Apoptotic Cell Death ELISA 162 
Cytoplasmic fraction in equal amount was prepared from mouse donor hearts 24-hour 163 
post implantation and was used to detect cell death using a commercially available Cell Death 164 
Detection ELISA kit (Roche Applied Science). Cytoplasmic histone-associated DNA fragments 165 
 9
were determined in duplicates of the samples and ELISA was conducted based on the 166 
manufacturer’s instruction. 167 
Transmission electron microscope 168 
The morphology of exosomes was determined by TEM. Isolated EVs were fixed with 4% 169 
formaldehyde. Three hundred mesh grids were placed under the sample and allowed to absorb 170 
overnight at 4°C. The grids were then dried and stained with Nanovan. The grids were viewed 171 
with images taken by a CCD camera. 172 
Western Blotting 173 
EVs, MSCs and MSC-CM were lysed by RIPA buffer containing Halt Protease Inhibitor 174 
Cocktail (ThermoFisher Scientific). The protein extracts were electrophoresed and the gel was 175 
transferred to a nitrocellulose membrane. The primary antibodies against CD63 (System 176 
Biosciences), Flotillin1 and GM130 (Cell Signaling Technology), and goat anti-rabbit IgG 177 
secondary antibody were employed.  The images were detected by GE CCD camera-based 178 
imager.  179 
Real-time PCR 180 
Total RNA was extracted from donor mouse hearts, MSCs, and MSC-EVs using 181 
miRNeasy Mini kit (Qiagen). 20 ng of total RNA from each preparation was used for the first-182 
strand cDNA reverse transcription using TaqMan microRNA reverse transcription kit 183 
(ThermoFisher Scientific) with primers of U6 snRNA (NR_004394, TaqMan microRNA control 184 
assay), microRNA (miR)-199a-3p (002304), and miR-199a-5p (000498). We selected to study 185 
miR-199a family because miR-199a-3p was identified as one of the most altered miRNAs in 6hr-186 
I + adipose tissue-derived MSC-CM mouse hearts (Fig. S2). Transcript levels were then 187 
determined by Real-time PCR (Light Cycler 96, Roche) using U6 snRNA TaqMan miR control 188 
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assay and TaqMan miR-199a-3p assay (ThermoFisher Scientific). The expression of miR-199a-189 
3p and miR-199a-5p was normalized to U6 snRNA levels using the standard 2−∆CT methods. 190 
Cytokine ELISA 191 
Donor hearts from 24-hour post-transplantation were homogenized in cold RIPA buffer. 192 
Supernatant was utilized for analyzing protein levels of IL-1β, IL-6, and TNF-α by ELISA 193 
(DY401 [IL-1β], DY406 [IL-6], and DY410 [TNF-α]; R&D Systems Inc.) based on the 194 
manufacturer’s instructions. All samples and standards were measured in duplicate. 195 
Proteome Profiler Mouse Cytokine Array 196 
A membrane-based antibody array (ARY006, R&D Systems Inc.) was utilized to detect 197 
40 cytokines and chemokines according to the manufacturer’s instructions. Equal protein amount 198 
(100 µg/sample) of four samples from each group (6hr-I, 6hr-I+MSC-CM, and 6hr-I+MSC-EVs) 199 
was pooled for the array. The signal densities were analyzed using the ImageJ. 200 
Statistical Analysis 201 
The reported results are shown as box-and-whiskers plots with each dot for individual 202 
measurement. The primary outcomes are cardiac function, including LVDP, +/- dP/dt, rate 203 
pressure product (RPP), and heart rate. Data were checked for variables using Shapiro-Wilk 204 
normality test and then analyzed using either one-way ANOVA with Tukey’s post-hoc analysis 205 
or t-test. Three data sets not passed for normality test were evaluated using either Kruskal-Wallis 206 
test or Mann Whitney test. Difference was considered statistically significant when p <0.05. All 207 
statistical analyses were performed using the GraphPad Prism software. 208 
Results 209 
Six-hour cold ischemia delayed recovery of donor hearts and impaired myocardial function 210 
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Fig. 1A and 1B show a mouse containing two beating hearts with two distinct QRS 211 
complex morphologies. Notably, the implanted hearts in 6hr-I groups took longer time to resume 212 
their spontaneous sinus rhythm (re-beating time) compared to those hearts in <1hr-I group (Fig. 213 
1C), implying that the longer storage time, the more delayed recovery donor hearts encountered. 214 
However, adding MSC-CM to UW solution significantly improved donor heart recovery, as 215 
demonstrated by decreased re-beating time in these hearts. 216 
Ventricular dysfunction within the first 24 hours of heart transplantation is the primary 217 
diagnostic criterion for primary graft failure. Therefore, we investigated LV function of 218 
implanted hearts at 24 hours post operation. Significantly impaired myocardial function (Fig. 219 
2A-E) was observed at 24 hours after surgery in transplanted hearts with 6hr-I compared to those 220 
being stored <1 hour, as shown by decreased LVDP and dP/dt, impaired - dP/dt, reduced RPP 221 
and heart rate. The functional parameters in MSC-CM-treated donor hearts were comparable to 222 
those hearts underwent minimal ischemia (<1hr-cold storage), suggesting that MSC-CM could 223 
reverse the detrimental effects of prolonged cold ischemia on myocardial function. Of note, there 224 
were no heart rate variance (Fig. S3) and pulse pressure differences (Fig. S4) in the native hearts 225 
among groups, providing additional experimental controls not only to indicate high 226 
reproducibility of our heterotopic heart transplantation model, but also to exclude MSC-CM-227 
improved myocardial functional preservation attributable to potential procedural variability. 228 
Furthermore, our results revealed that the CMC did not covey functional protection in donor 229 
hearts following 6hr-I (Fig. S5A-D). 230 
Six-hour cold ischemia induced tissue damage 231 
Based on H&E-stained heart sections (Fig. 3A), six-hour cold ischemia did not cause 232 
much histological alterations and only resulted in slight inflammation and thrombus in heart 233 
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grafts at 24h after transplantation. However, more apoptotic-related dead cells were observed in 234 
the 6hr-I hearts than in the <1hr-I group (Fig. 3B). Using MSC-CM protected the myocardium 235 
against prolonged cold ischemia, as shown by comparable dead cells between these hearts and 236 
the <1hr-I group (Fig. 3B).   (Fig. 3B). 237 
MSC extracellular vesicles conferred MSC-CM-mediated myocardial functional preservation 238 
following 6hr cold ischemia 239 
MSC-derived EVs (exosomes and micro-vesicles) are critical components involved in 240 
paracrine protection of MSC secretome. We confirmed the presence of exosomes in the 241 
preparation of MSC-EVs by TEM (Fig. 4A). Nanosight analysis was used to determine size 242 
distribution of MSC-EVs. The most abundant nanoparticles were observed at 94 nm as seen in 243 
the peak of histogram (Fig. 4B). We also noticed > 150 nm nanoparticles in our preparation, 244 
suggesting that MSC-derived micro-vesicles were in these samples as well. We further verified 245 
the MSC-EVs by Western blot analysis. The MSC-EVs expressed exosomal markers of CD63 246 
and Flotillin1 (Fig. 4C), whereas these EVs were free of cell debris contamination as shown by 247 
undetected signal of GM130 (a Golgi marker). Intriguingly, replacing MSC-CM with MSC-EVs 248 
to supplement UW solution for ex-vivo heart storage revealed that MSC-EVs preserved 249 
myocardial function against cold ischemia and reperfusion (Fig. 4D-4G). Likewise, using MSC-250 
EVs reduced apoptotic-related cell death in the 6hr-I hearts compared to their untreated 251 
counterparts (Fig. 4I). To further validate the protective effect of MSC-Exo on donor heart 252 
function, we utilized MSC-CM from MSCs treated with an exosome release inhibitor (GW4849). 253 
As shown in Figure 5, depletion of exosomes in MSC-CM partially neutralized MSC-CM-254 
mediated protection in donor hearts. 255 
Cold ischemia reduced myocardial expression of miR-199a-3p that was enriched in MSC-EVs 256 
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Based on another individual study of the deep miRNA sequencing analysis, miR-199a-3p 257 
was identified as one of the most altered miRNAs in 6hr-I + human adipose tissue-derived MSC-258 
CM mouse hearts (Fig. S2). Additionally, given that one of the important functions of exosomes 259 
is to transport miRNAs, we therefore selected miR-199a-3p to study the role of MSC-Exo in 260 
transferring miR to donor hearts following ex-vivo cold storage. First, we observed a markedly 261 
higher level of miR-199a-3p in MSC-EVs than in MSCs themselves (Fig. 6A) and baseline heart 262 
tissue (Fig. 6B), providing a possibility of transferring this miR from highly enriched MSC-EVs 263 
to the heart. Next, we investigated the temporal alteration of miR-199a-3p expression in mouse 264 
donor hearts following cold storage but without transplantation. We found that 6hr-cold ischemia 265 
led to significantly reduced myocardial miR-199a-3p expression (Fig. 6C), whereas using MSC-266 
CM or MSC-EVs restored its level. In addition, depletion of exosomes in MSC-CM abolished 267 
MSC-CM- or EVs-increased miR-199a-3p levels in donor hearts (Fig.6C). Such cold ischemia-268 
downregulated miR-199a-3p persisted in heart grafts at 24-hour post-transplantation, but MSC-269 
CM restored myocardial expression of miR-199a-3p (Fig. 6D). Furthermore, using MSC-EVs 270 
significantly increased myocardial miR-199a-3p levels (Fig. 6E) and inhibition of exosomes 271 
released into MSC-CM abolished MSC-CM-improved myocardial expression of this miRNA in 272 
the heart graft 24 hours post-implantation (Fig. 6F). However, we did not observe the similar 273 
results for miR-199a-5p expression in donor hearts (Fig. S6). 274 
Myocardial cytokine production following ex-vivo cold storage 275 
Locally produced cytokines contribute to cardiac dysfunction. Following 24-hour 276 
transplantation, significantly reduced pro-inflammatory cytokine production (TNFα, IL-1β and 277 
IL-6) was observed in implanted hearts of 6hr-I+MSC-CM and 6hr-I+MSC-EVs compared with 278 
6hr-I+vehicle (Fig. 7A). Moreover, by using an antibody array, MSC-CM or MSC-EVs were 279 
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shown to reduce multiple cytokines/chemokines in these donor hearts, including C5/C5a, 280 
sICAM-1, CXCL1 and CCR2/MCP-1 etc. (Fig. 7B), suggesting that MSC-CM- or MSC-EV-281 
regulated myocardial production of cytokines/chemokines may be an underlying mechanism for 282 
their mediated-protection in grafts after transplantation.   283 
Discussion 284 
Our results represent the first evidence that the MSC secretions, particular MSC-EVs, as 285 
an adjunct to preservation solution provides a protective effect on donor hearts against prolonged 286 
cold ischemia during ex-vivo static storage in a murine heterotopic heart transplantation model 287 
(Fig. 8). A recent paper has shown that preservation solution supplemented with MSC-CM 288 
protects the heart function in 15-month-old rats using hypothermic oxygenated perfusion for 289 
donor heart storage 21. In contrast, our study focusing on heart graft improvement during cold 290 
static storage possesses more practical benefit in the clinical setting given that cold static storage 291 
is the standard approach for organ preservation. In addition, by using miR-199a-3p as a 292 
representative miRNA, in the first time, we demonstrate that MSC-EVs serve as a vehicle to 293 
mediate the transfer of miR-199a-3p from MSCs to donor hearts during their ex-vivo cold 294 
storage. Such findings support the notion of EV-based gene therapy for miR delivery. It is worth 295 
mentioning that MSC secretions or MSC-EVs can be readily prepared in compliance with good 296 
manufacturing practice, stored as off-the-shelf material, and used for therapy promptly without 297 
the need for either cell isolation or thawing of stored cells, each of which poses significant 298 
practical barriers to widespread adoption of cell therapies in this context. More importantly, 299 
using MSC secretions or MSC-EVs as potential therapeutic modality could circumvent the risks 300 
associated with cell therapies. Therefore, our findings provide a foundation to develop cell-free, 301 
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secretome-based therapies for optimization of current storage methods, thus improving donor 302 
organ function (Fig. 8). 303 
The heart is more susceptible to ischemic injury compared with other solid organs 304 
because of its innately high metabolic demands. I/R injury is a critical factor to influence graft 305 
function and clinical outcome after organ transplantation. Accumulated evidence from our 306 
previous studies has shown that MSC-derived paracrine action promotes cell survival and overall 307 
myocardial function while reducing inflammation and tissue damage following myocardial 308 
ischemia 9, 12-14, 22, 23. Infusion of MSC-CM at the onset of reperfusion also provides 309 
cardioprotection against myocardial I/R injury in an ex-vivo model 24. In this study, our findings 310 
that using MSC-CM improved post-implanted heart recovery, with shorter re-beating time and 311 
preserved LV contractile and diastolic function following prolonged cold ischemia, as well as 312 
reduced cell death and decreased inflammatory cytokine production extend our previous studies, 313 
in which MSC-CM protected myocardium from warm I/R injury 9; and our initial description of 314 
secretome therapeutic utility, in which MSC-secretome protected brain from ischemic injury 11. 315 
Of note, extracellular vesicles, particularly exosomes, have emerged as essential 316 
components of the MSC secretome to mediate protective effects 25-27. Our study confirms that 317 
MSC-EVs confer protection in donor hearts following ex-vivo cold storage. MSC-EVs have been 318 
shown to transport functional proteins, mRNAs and miRNAs to target cells, acting as mediators 319 
of MSC paracrine action 17. Among these, a key form of functional RNAs in exosomes is 320 
miRNA that delivers gene regulatory information and thus can change the physiology of 321 
recipient cells. In the present study, we observed that cold ischemia led to prominent disruption 322 
of miR-199a-3p expression. However, using MSC-CM markedly restored the reduced miR-199a-323 
3p levels in donor hearts with 6hr-cold ischemia. Our results revealed that there are highly 324 
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enriched miR-199a-3p in MSC-EVs and significantly increased miR-199a-3p levels in MSC-EV-325 
treated donor hearts, and exosome-depleted MSC-CM leads to abolished MSC-CM-restored 326 
miR-199a-3p in transplanted hearts. Taking altogether, we reasoned that miR-199a-3p could be 327 
transported from MSC exosomes into donor hearts. Notably, a single-dose intracardiac injection 328 
of miR-199a-3p has been shown to improve cardiac function following myocardial infarction 28. 329 
In addition, miR-199a-3p plays a pivotal role in regulating cardiomyocyte survival in response to 330 
simulated I/R 29. Furthermore, miR-199a-3p is identified as one of several miRNAs critical to 331 
induce cardiac regeneration 30. Therefore, during ischemic cold storage, MSC-CM- or MSC-EV-332 
induced cardiac protection in donor hearts could partially be attributable to the MSC-EV-333 
transferred miRs, like miR-199a-3p. However, the detailed mechanism regarding this requires 334 
further investigation in the future. 335 
MSC secretion also contains the multiple tropic factors released from MSCs. The MSC 336 
secreted factors, including VEGF, HGF, and SDF-1, have been well defined for their effects on 337 
angiogenesis and anti-apoptosis from our previous studies 12-14, 23, 31. Such MSC-derived factors 338 
could provide protective activity to donor hearts against cold ischemia. In fact, our current study 339 
confirmed that exosome-depleted MSC-CM was still able to protect donor hearts against cold 340 
ischemia and subsequent reperfusion to some degree, suggesting the involvement of MSC-341 
released soluble factors in donor heart protection. 342 
We have previously shown that injection of MSCs into the heart improved cardiac 343 
function and reduced local inflammation following myocardial ischemia 9, 10. Here,  we observed 344 
that adding MSC-CM or MSC-EVs to UW solution significantly decreased pro-inflammatory 345 
cytokine production (TNFα, IL-1β and IL-6) and a panel of cytokines/chemokines in heart grafts 346 
after transplantation, implying that MSC secretome-affected myocardial cytokines contribute to 347 
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regulating graft function. This mechanism could play a more important role in an 348 
allotransplantation model.  349 
In this study, we lack evidence supporting the necessity of MSC-derived exosomal 350 
miRNAs, including miR-199a-3p, for MSC-CM-based improvement in donor heart preservation. 351 
The isotransplantation utilized here also limits us on evaluating the effect of MSC secretome and 352 
MSC-EVs on modulating inflammation and immune responses between transplanted heart and 353 
recipient. Clarifying these mechanisms and the implications of MSC-Exo miRNAs in donor 354 
heart preservation will require further study in the future. Albeit these limitations, our study 355 
provides the important translational evidence that the presence of MSC-CM or MSC-EVs in ex-356 
vivo storage solution protects donor hearts against prolonged cold ischemia and improves organ 357 
function after transplantation in a mouse model. Additionally, this initial study indicates that  358 
MSC-EV-mediated intercellular transport of miRNAs may be used as EV-based gene therapy for 359 
miRNA delivery in the heart transplant field.  360 
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Figure Legend 462 
Figure 1. The cervical heterotopic heart transplantation. A. Donor hearts from C57BL/6 male 463 
mice were implanted into C57BL/6 male recipient mice. The cervical skin was closed after the 464 
implanted heart was observed to resume normal sinus rhythm. B. The ECG indicated two distinct 465 
QRS complex morphologies: the graft vs. native heart post transplantation. C. Re-beating time 466 
(the time for implanted donor hearts to resume their spontaneous sinus rhythm after 467 
transplantation) among groups of < 1hr-cold ischemia (I), 6hr-I + vehicle and 6hr-I + MSC-CM 468 
(mesenchymal stem cell conditioned media). There was longer time for returning spontaneous 469 
sinus rhythm in the implanted hearts of the 6hr-I group compared to those hearts in <1hr-I group. 470 
Adding MSC-CM to UW (University of Wisconsin) solution markedly shortened the time to 471 
resume sinus rhythm in these donor heart at the reperfusion.  *p<0.05, ****p<0.001. The upper 472 
and lower borders of the box indicate the upper and lower quartiles; the middle horizontal line 473 
represents the median; and the upper and lower whiskers show the maximum and minimum 474 
values. Dots represent individual measurements. 475 
Figure 2. MSC conditioned medium (MSC-CM) preserves Left ventricular function in implanted 476 
hearts at 24-hour post transplantation. A. Left ventricular developed pressure (LVDP = LV 477 
systolic pressure – LV end diastolic pressure). B. The maximum value of the first derivative 478 
(dP/dt). C. The maximum negative value of the first derivative (- dP/dt). D. Rate Pressure 479 
Product (RPP = LVDP X Heart rate BPM). E. Normalized heart rate of the implanted hearts to 480 
native heart rate. Six-hour cold storage (cold ischemia – I) impaired donor heart function, as 481 
demonstrated by decreases in LVDP, dP/dt, RPP, and normalized heart rate and damaged -dP/dt 482 
when compared to the < 1hr-I group. However, adding MSC-CM to UW solution for donor heart 483 
preservation restored these functional parameters. *p<0.05, **p<0.01. The upper and lower 484 
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borders of the box indicate the upper and lower quartiles; the middle horizontal line represents 485 
the median; and the upper and lower whiskers show the maximum and minimum values in all 486 
box-and-whiskers graphs. Dots represent cardiac functional measurements of heart grafts. 487 
Figure 3. The influence of six-hour cold ischemia (I) on myocardial microstructure and 488 
apoptosis-related cell death in donor hearts at 24 hours after implantation. A. Representative 489 
micrographs (H&E straining) showing slight inflammation and thrombus in donor hearts. Six-490 
hour cold ischemia did not cause much histological alterations. Magnification 40X (upper panel) 491 
and 200X (lower panel). B. Myocardial apoptotic cell death at 24 hours post-transplantation. 492 
Cytoplasmic histone-associated DNA fragments were measured in the implanted hearts of <1hr-493 
I, 6hr-I+vehicle and 6hr-I+MSC-CM. Results expressed as absorbance. Compared to the <1hr-I 494 
group, significantly increased apoptotic-related dead cells were observed in the 6hr-I hearts, but 495 
not in 6hr-I+MSC-CM group. **p<0.01. The upper and lower borders of the box indicate the 496 
upper and lower quartiles; the middle horizontal line represents the median; and the upper and 497 
lower whiskers show the maximum and minimum values in all box-and-whiskers graphs. Dots 498 
represent individual measurements. 499 
Figure 4. Modified preservation solution by using MSC-derived extracellular vesicles (MSC-500 
EVs) provides improved protection in donor hearts during ex-vivo cold storage. A. The 501 
morphology and size of exosomes were observed under transmission electron microscope. B. 502 
Size distribution of MSC-EVs by Nanosight analysis. EVs were isolated from MSCs cultivation 503 
with serum free medium for 72 hours and 5 µg of EVs was used for Nanosight analysis. C. 504 
Western blot analysis in MSC-EVs for the presence of exosomal markers CD63 and Flotillin1. 505 
GM130 as a negative control.  D. LVDP. E. dP/dt. F. - dP/dt. G. RPP. H. Normalized heart rate 506 
of the implanted hearts. I. Apoptotic-related cell death in donor hearts. Donor hearts preserved in 507 
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UW solution containing MSC-EVs for 6 hours demonstrated better graft function and lower level 508 
of apoptotic-related cell death at 24 hours post-implantation than those in 6hr-I + vehicle group. 509 
*p<0.05, **p<0.01, ***p<0.001. The upper and lower borders of the box indicate the upper and510 
lower quartiles; the middle horizontal line represents the median; and the upper and lower 511 
whiskers show the maximum and minimum values in all box-and-whiskers graphs. Dots 512 
represent individual measurements. 513 
Figure 5. Exosome-depleted MSC-CM confers compromised protection in donor hearts at 24 514 
hours post-transplantation. A LVDP. B. dP/dt. C. - dP/dt. D. RPP. E. Normalized heart rate of 515 
the implanted hearts. F. Apoptotic-related cell death in donor hearts. CM collected after MSCs 516 
were treated with 10 µM GW4869 (an inhibitor of exosome release) for 72 hours (CMGW4869) 517 
was added to UW solution for ex vivo storage of donor hearts. CMGW4869 did not provide 518 
comparable protection in donor hearts following 6hr-cold ischemia (6hr-I) as normal MSC-CM 519 
(without using GW4869) did. Significantly decreased graft function (LVDP and RPP) was 520 
noticed in the CMGW4869 group compared to MSC-CM group. *p<0.05, **p<0.01, 521 
****p<0.0001. The upper and lower borders of the box indicate the upper and lower quartiles; 522 
the middle horizontal line represents the median; and the upper and lower whiskers show the 523 
maximum and minimum values in all box-and-whiskers graphs. Dots represent individual 524 
measurements. 525 
Figure 6. The possibility of transferring miR-199a-3p from MSC-EVs to myocardium. A. 526 
Highly enriched miR-199a-3p in MSC-EVs compared with its cellular level in MSCs. B Much 527 
higher levels of miR-199a-3p in MSC-EVs than in baseline mouse heart tissue. C. Using MSC-528 
CM or MSC-EVs in UW solution for ex-vivo preservation restored miR-199a-3p level that was 529 
reduced by six-hour cold ischemia in donor hearts without transplantation, whereas much lower 530 
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levels of miR-199a-3p were observed in the group of 6hr-I+CMGW4869. D. Adding MSC-CM to531 
UW solution for ex-vivo storage preserved myocardial miR-199a-3p expression in implanted 532 
donor hearts at 24 hours post-transplantation. E. Using MSC-EVs in UW solution increased cold 533 
ischemia-downregulated miR-199a-3p in transplanted mouse hearts. F. Depletion of exosomes in 534 
MSC-CM abolished MSC-CM-preserved miR-199a-3p expression in donor hearts post 535 
implantation. After normalized to U6 snRNA, the relative miR-199a-3p transcript levels are 536 
represented as folds of a control sample in different graphs, respectively. *p<0.05, **p<0.01, 537 
***p<0.001. The upper and lower borders of the box indicate the upper and lower quartiles; the 538 
middle horizontal line represents the median; and the upper and lower whiskers show the 539 
maximum and minimum values in all box-and-whiskers graphs. Dots represent individual 540 
measurements. 541 
Figure 7. Myocardial cytokine production in donor hearts 24 hours post-transplantation. A. 542 
TNFα, IL-1β, and IL-6 levels were determined in donor hearts of 6hr-I + vehicle, 6hr-I + MSC-543 
CM and 6hr-I + MSC-EVs groups by ELISA. Adding MSC-CM or MSC-EVs to UW solution 544 
for donor heart preservation significantly decreased myocardial TNFα, IL-1β and IL-6 545 
production at 24 hours post-transplantation compared to vehicle group. *p<0.05, **p<0.01, 546 
***p<0.001. The upper and lower borders of the box indicate the upper and lower quartiles; the 547 
middle horizontal line represents the median; and the upper and lower whiskers show the 548 
maximum and minimum values in all box-and-whiskers graphs. Dots represent individual 549 
measurements. B. Multiple cytokines and chemokines were detected by a membrane-based 550 
antibody array using pooled protein samples (equal amount of proteins pooled from four samples 551 
per group in 6hr-I, 6hr-I+MSC-CM, and 6hr-I+MSC-EVs). All donor hearts were collected at 24 552 
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hours post-transplantation. The bar graph shows relative level of the cytokine signal density 553 
normalized to reference dots in each group. 554 
Figure 8. MSC secretions-optimized storage solution preserves donor hearts against cold 555 
storage and improves graft function post-surgery. Isolated donor hearts from C57BL/6 mice 556 
were infused with and subsequently stored in cold University of Wisconsin (UW) solution 557 
containing different additions. MSC-CM: mesenchymal stem cell conditioned media; EVs: 558 
MSC-derived extracellular vesicles; Exo-i: CM from MSCs treated with exosome (Exo) release 559 
inhibitor (GM4869). The two distinct QRS complex morphologies were also noticed in the 560 
recipient mice at 1-month, 5-month, and 12-month post-transplantation by the ECG follow-up. 561 
Video 1: Surgical procedure for murine heterotopic heart transplantation using cuff technique. 562 
The anastomoses between the donor heart and the recipient animal were performed using the 563 
cuffs to connect donor pulmonary artery to recipient right external jugular vein and donor aorta 564 
to recipient common carotid artery, respectively.  565 
















